Future Science Group
Supplemental_Table.docx (21.19 kB)
Download file

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study - supplementary table

Download (21.19 kB)
posted on 2023-08-23, 10:33 authored by Daniel Bensimhon, William S Weintraub, William Frank Peacock, Tamas Alexy, Dalton McLean, Donald Haas, Kathleen L Deering, Stefanie J Millar, Matthew M Goodwin, John F Mohr

Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5- h subcutaneous infusion for 7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <72 h. Results: Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. Sixty-six control patients identified and were wellmatched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p < 0.001). Conclusion: Furoscix use was associated with significant reductions in 30-day HF-related healthcare costs versus matched hospitalized controls.


scPharmaceuticals, (Grant / Award Number: 'scPharmaceuticals served as study sponsor')


Usage metrics

    Future Cardiology